---
title: "Guanhao Biotech Co., Ltd. (300238.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300238.SZ.md"
symbol: "300238.SZ"
name: "Guanhao Biotech Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-21T07:39:30.915Z"
locales:
  - [en](https://longbridge.com/en/quote/300238.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300238.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300238.SZ.md)
---

# Guanhao Biotech Co., Ltd. (300238.SZ)

## Company Overview

Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Type B dura, a spinal patch; Sterile Bio Wound Membrane; Ario Mesh; Thoracic Surgery Repair Diaphragm; and Cympic Benvimod Cream for psoriasis.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.guanhaobio.com](https://www.guanhaobio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:14.000Z

**Overall: C (0.44)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 58 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.46% |  |
| Net Profit YoY | -29.58% |  |
| P/B Ratio | 5.92 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3427165256.85 |  |
| Revenue | 385653850.21 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3.45% | C |
| Profit Margin | 5.08% | C |
| Gross Margin | 76.64% | A |
| Revenue YoY | 1.46% | C |
| Net Profit YoY | -29.58% | D |
| Total Assets YoY | 3.01% | C |
| Net Assets YoY | 1.35% | C |
| Cash Flow Margin | 216.77% | B |
| OCF YoY | 1.46% | C |
| Turnover | 0.50 | C |
| Gearing Ratio | 37.13% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Guanhao Biotech Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.46%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-29.58%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.92",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3427165256.85",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "385653850.21",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "3.45%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "5.08%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "76.64%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1.46%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-29.58%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.01%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.35%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "216.77%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "1.46%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.50",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "37.13%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 174.82 | 38/81 | 167.22 | 157.99 | 147.54 |
| PB | 5.92 | 58/81 | 7.86 | 7.29 | 6.79 |
| PS (TTM) | 8.89 | 41/81 | 11.45 | 10.63 | 9.94 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300238.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300238.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300238.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300238.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**